Predicting Treatment Outcome in Chronic Myeloid Leukemia

Achieving a BCR-ABL1 transcript level of <10% at 3 months after initiation of imatinib therapy was associated with improved survival for patients with chronic-phase CML.

Hematologic, cytogenetic, and molecular response assessments are an established component of managing chronic myeloid leukemia (CML) patients with tyrosine kinase inhibitors (TKIs). To correlate BCR-ABL1 transcript levels at 3, 6, and 12 months after the initiation of first-line imatinib therapy (400 mg daily) with overall survival (OS) and progression-free survival (PFS), investigators conducted a single-institution study involving 282 consecutive patients with chronic-phase CML who underwent BCR-ABL1 transcript measurements every 6 to 12 weeks. Patients who did not tolerate or respond to imatinib could be switched to nilotinib or dasatinib. Molecular results were determined by real-time quantitative polymerase chain reaction (RQ-PCR) and …

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee